{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:53:30Z","timestamp":1790780010023,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81800590"],"award-info":[{"award-number":["81800590"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81670611"],"award-info":[{"award-number":["81670611"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81874094"],"award-info":[{"award-number":["81874094"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81902858"],"award-info":[{"award-number":["81902858"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81974397"],"award-info":[{"award-number":["81974397"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012579","name":"Natural Science Foundation of Qinghai","doi-asserted-by":"crossref","award":["2020JJ5882"],"award-info":[{"award-number":["2020JJ5882"]}],"id":[{"id":"10.13039\/501100012579","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012579","name":"Natural Science Foundation of Qinghai","doi-asserted-by":"crossref","award":["2020JJ5949"],"award-info":[{"award-number":["2020JJ5949"]}],"id":[{"id":"10.13039\/501100012579","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the efficacy and safety of everolimus and sirolimus in patients with tuberous sclerosis complex-associated angiomyolipomas (TSC-AML).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>\n  We performed a multi-institutional retrospective study of TSC-AML patients treated with oral everolimus 10\u00a0mg or sirolimus 2\u00a0mg per day for at least 3 months. Angiomyolipoma volume was estimated using orthogonal measurements by MRI or CT. Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events. All analyses were performed using SPSS 19.0 software.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Response rates were high in both groups. With the prolonged medication durations, the therapeutic efficacy of both agents became more significant. The TSC-AML volume reduction after 6 and 12 months was more pronounced in patients with everolimus than those with sirolimus. More than half of the patients treated with everolimus had\u2009\u2265\u200950% reduction, and approximately 80% of them had\u2009\u2265\u200930% reduction, which was higher than that in patients treated with sirolimus. Regarding safety, there was no significant difference in the incidence of AEs between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Both everolimus and sirolimus are excellent therapeutic options for TSC-AML. However, everolimus has a better therapeutic efficacy than sirolimus, particularly in reducing TSC-AML volume. Everolimus is therefore recommended as the first choice of therapy for TSC-AML.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01932-z","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T13:02:29Z","timestamp":1625317349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China"],"prefix":"10.1186","volume":"16","author":[{"given":"Cong","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Zhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong-Bin","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"key":"1932_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","volume":"615","author":"JP Osborne","year":"1991","unstructured":"Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125\u20137.","journal-title":"Ann N Y Acad Sci"},{"key":"1932_CR2","doi-asserted-by":"publisher","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske EP, J\u00f3\u017awiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1932_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","volume":"66","author":"CW Shepherd","year":"1991","unstructured":"Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66(8):792\u20136.","journal-title":"Mayo Clin Proc."},{"issue":"15","key":"1932_CR4","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1101\/gad.1110003","volume":"17","author":"K Inoki","year":"2003","unstructured":"Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17(15):1829\u201334.","journal-title":"Genes Dev"},{"issue":"1","key":"1932_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.braindev.2018.07.003","volume":"41","author":"M Mizuguchi","year":"2019","unstructured":"Mizuguchi M, Ikeda H, Kagitani-Shimono K, Yoshinaga H, Suzuki Y, Aoki M, et al. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. Brain Dev. 2019;41(1):1\u201310.","journal-title":"Brain Dev"},{"issue":"9869","key":"1932_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324.","journal-title":"Lancet"},{"issue":"1","key":"1932_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","volume":"153","author":"M Wataya-Kaneda","year":"2017","unstructured":"Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S, Yamamoto K, et al. Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol. 2017;153(1):39\u201348.","journal-title":"JAMA Dermatol"},{"issue":"9861","key":"1932_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u201332.","journal-title":"Lancet"},{"issue":"10","key":"1932_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7164\/antibiotics.28.721","volume":"28","author":"C V\u00e9zina","year":"1975","unstructured":"V\u00e9zina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28(10):721\u20136.","journal-title":"J Antibiot (Tokyo)"},{"issue":"8","key":"1932_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","volume":"40","author":"K Mahalati","year":"2001","unstructured":"Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40(8):573\u201385.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1932_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","volume":"43","author":"GI Kirchner","year":"2004","unstructured":"Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83\u201395.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1932_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8):671\u201388.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1932_CR13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/ndt\/gfy132","volume":"34","author":"JJ Bissler","year":"2019","unstructured":"Bissler JJ, Budde K, Sauter M, Franz DN, Zonnenberg BA, Frost MD, et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol Dial Transplant. 2019;34(6):1000\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1932_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"1932_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13023-019-1012-x","volume":"14","author":"M Li","year":"2019","unstructured":"Li M, Zhou Y, Chen C, Yang T, Zhou S, Chen S, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1932_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-018-0781-y","volume":"13","author":"Y Cai","year":"2018","unstructured":"Cai Y, Guo H, Wang W, Li H, Sun H, Shi B, et al. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet J Rare Dis. 2018;13(1):43.","journal-title":"Orphanet J Rare Dis"},{"key":"1932_CR17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.5694\/j.1326-5377.1964.tb115780.x","volume":"2","author":"B Gandevia","year":"1964","unstructured":"Gandevia B, Tovell A. Declaration of Helsinki. Med J Aust. 1964;2:320\u20131.","journal-title":"Med J Aust"},{"issue":"2","key":"1932_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000448293","volume":"134","author":"JC Kingswood","year":"2016","unstructured":"Kingswood JC, Bissler JJ, Budde K, Hulbert J, Guay-Woodford L, Sampson JR, et al. Review of the tuberous sclerosis renal guidelines from the 2012 consensus conference: current data and future study. Nephron. 2016;134(2):51\u20138.","journal-title":"Nephron."},{"issue":"3","key":"1932_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/odi.12616","volume":"23","author":"S Sonis","year":"2017","unstructured":"Sonis S, Andreotta PW, Lyng G. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa. Oral Dis. 2017;23(3):347\u201352.","journal-title":"Oral Dis"},{"issue":"5","key":"1932_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40265-016-0552-9","volume":"76","author":"P Curatolo","year":"2016","unstructured":"Curatolo P, Bj\u00f8rnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, et al. The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions. Drugs. 2016;76(5):551\u201365.","journal-title":"Drugs"},{"issue":"3","key":"1932_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ajmg.c.31655","volume":"178","author":"DN Franz","year":"2018","unstructured":"Franz DN, Krueger DA. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):365\u201373.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"4","key":"1932_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1432-2277.2006.00423.x","volume":"20","author":"E Huyghe","year":"2007","unstructured":"Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int. 2007;20(4):305\u201311.","journal-title":"Transpl Int"},{"issue":"1","key":"1932_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1046\/j.1600-6135.2003.00279.x","volume":"4","author":"L Fritsche","year":"2004","unstructured":"Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant. 2004;4(1):130\u20131.","journal-title":"Am J Transplant"},{"issue":"11","key":"1932_CR24","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1056\/NEJMc1113145","volume":"366","author":"M Braun","year":"2012","unstructured":"Braun M, Young J, Reiner CS, Poster D, W\u00fcthrich RP, Serra AL. Ovarian toxicity from sirolimus. N Engl J Med. 2012;366(11):1062\u20134.","journal-title":"N Engl J Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01932-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01932-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01932-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T13:12:35Z","timestamp":1625317955000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01932-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1932"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01932-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"11 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the <i>Declaration of Helsinki<\/i> and local regulations.  This study was approved by the Institutional Review Board of Xiangya Hospital, Central South University, the Institutional Review Board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College and the Institutional Review Board of the Affiliated Hospital of Qingdao University.  All patients signed written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients with individual data presented have signed a written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}